First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid TumorsAnna Schreiber, Jennifer R. Diamond|Cancers|2023Cited by 10